ABCC8
ATP-binding cassette sub-family C member 8
As of the edition of 20 October 2026, ABCC8 (ATP-binding cassette sub-family C member 8, UniProt Q09428) has 13 drugs tested at it and 18 companies on the list, 0 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q09428
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Nervous system; Urinary and reproductive; Pregnancy and women's health; Cancer; Digestive system
- Registered trials of its drugs
- 304
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Glimepiride | Marketed | Phase 4 | none listed |
| Glyburide | Marketed | Phase 4 | none listed |
| Repaglinide | Marketed | Phase 4 | none listed |
| Gliclazide | Marketed | Phase 4 | none listed |
| Tolbutamide | Marketed | Phase 1 | none listed |
| Glipizide | Marketed | Phase 4 | none listed |
| Nateglinide | Marketed | Phase 4 | none listed |
| Mitiglinide | Marketed | Phase 4 | none listed |
| Acetohexamide | Marketed | Phase 3 | none listed |
| Mitiglinide calcium dihydrate | Marketed | Phase 4 | none listed |
| Chlorpropamide | Marketed | No phase stated | none listed |
| Gliquidone | Marketed | Phase 4 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 9 |
| Undetermined | 9 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Sanofi | Route B |
| Novo Nordisk | Route B |
The other 15 companies at ABCC8
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at ABCC8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.